PATENT Docket No. 290.00500101

	IN THE UNITED STAT	ES PATEN	T AND TRADEMARI	K OFFICE	RECEIVED CENTRAL FAX CEN
Applicant(s):	SANDERS et al.	)	Group Art Unit:	1648	MAY 1 2 2008
Serial No.:	10/516,578	į	Examiner:	Bo Peng	2 2008
§ 371 Date: Int'l Filing Date:	16 November 2005 4 June 2003	)	Confirmation No.:	5513	
For:	IMPROVED PSEUDO	TYPED RET	roviruses		
	FACSIMILE	TRANSMIS	SSION TO THE PTO	<u> </u>	
Commissioner for Patents Mail Stop Missing Parts P.O. Box 1450 Alexandria, VA 22313-1450			FAX NUMBER:	ng cover page (Central Tirbe complete b	): <u>14</u> me)
transmission: Applications pgs): a Reque	g papers are being trans  A Communication  Containing Nucleotide  est for Transfer of Containent (3 pgs); a W	n Re: Notic Sequence a nputer Rea	e to Comply with Ro nd/or Amino Acid S dable Form of Seque	equirements equence Disc ence Listing	for Patent closures (2 (2 pgs); a
Please Charg	e Deposit Account No. 1	l3-4895 in t	he amount of	for the requi	ired fee.
	this a PETITION FOR EXT I please charge any addition				
Moug I	L, wb	Custo By: Victor Reg. N	ng, Raasch & Gebhard paer Number: 26813 Lia A. Sandberg No. 41,287 Dial (612)305-1226	lt, P.A.	
paper(s), as descr Patent and Trade	UNDER 37 C.F.R. §1.8: The ibed hereinabove, are being to mark Office addressed to the 22313-1450, on this 127	ransmitted by t Commissioner	facsimile in accordance win for Patents, Mail Stop Mis 2008, at 1 05 Ah	th37 CFR §1.6(6	i) to the D. Box 1450,

Tf you do not receive all pages, please contact us at (612)305-1220 (ph) or (612)305-1228 (fax).

PAGE 1/14 \* RCVD AT 5/12/2008 12:08:23 PM [Eastern Daylight Time] \* SVR:USPTO-EFXRF-5/28 \* DNIS:2738300 \* CSID:6123051228 \* DURATION (mm-ss):06-36

05/12/2008 11:13 FAX 6123051228 MUETING RAASCH GEBHARDT

MAY 1 2 2008

	Application No. Applicant(s)						
	10/516,578	Sanders	s, David				
Notice to Comply	Examiner	Art Unit					
	Bo Peng, PH.D.	1648					
NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS							
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES							
Applicant must file the items indicated below within the time period set in the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).							
The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1,821 - 1,825 for the following reason(s):							
☑ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).							
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).							
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).							
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."							
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).							
6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).							
7. Other:							
Applicant Must Provide:  An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".							
An initial or substitute paper copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application.							
☑ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).							
For questions regarding compliance to these requirements, please contact:							
For Rules Interpretation, call (571) 272-2510 For CRF Submission Help, call (571) 272-2501/2583. PatentIn Software Program Support Technical Assistance							
PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY							

PATENT
Docket No. 290.0050010 CENTRAL FAX CENTRAL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY 1 2 2008

Applicant(s): SANDERS et al. ) Group Art Unit: 1648

Serial No.: 10/516,578 ) Examiner: Bo Peng

§ 371 Date: 16 November 2005 ) Confirmation No.: 5513

Int'l Filing Date: 4 June 2003

For: IMPROVED PSEUDOTYPED RETROVIRUSES

## COMMUNICATION RE: NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Mail Stop Missing Parts

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

In response to the Notice to Comply with Requirements for Patent Applications

Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosure dated April 10, 2008,

Applicants hereby submit a paper copy of the Sequence Listing for the above-identified application.

Applicants request that the Computer Readable Form of the Sequence Listing be transferred from International Application PCT/US03/17577, in accordance with the Request for Transfer of Computer Readable Form of Sequence Listing submitted herewith.

It is respectfully submitted that the information recorded in computer readable form is identical to the written Sequence Listing. Moreover, it is submitted that the Sequence Listing does not contain new matter.

Communication Re: Missing Parts

Applicant(s): SANDERS et al. Serial No.: 10/516,578 Confirmation No.: 5513 Filed: 16 November 2005

For: IMPROVED PSEUDOTYPED RETROVIRUSES

Page 2 of 2

Applicants believe there is no fee due at this time. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

Please direct any inquiries to the undersigned attorney.

## CERTIFICATE UNDER 37 C.F.R. 1.8:

The undersigned hereby certifies that this paper is being transmitted by facsimile in accordance with 37 CFR §1.6(d) to the Patent and Trademark Office, addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this day of May, 2008, at 11 Control Tirle) have and for the control Tirle have a control to the control that the control th

Date

Respectfully submitted

By

Mueting, Raasch & Gebhardt, P.A.

P.O. Box 581415

Minneapolis, MN 55458-1415

Phone: (612)305-1220 Facsimile: (612)305-1228 Customer Number 26813

Victoria A. Sandberg

Reg. No. 41,287

Direct Dial (612)305-1226